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ABSTRACT
Purpose A semi-mechanistic multiple-analyte population phar-
macokinetics (PK) model was developed to describe the complex
relationship between the different analytes of monomethyl
auristatin E (MMAE) containing antibody-drug conjugates
(ADCs) and to provide insight regarding the major pathways of
conjugate elimination and unconjugated MMAE release in vivo.
Methods For an anti-CD79b-MMAE ADC the PK of total antibody
(Tab), conjugate (evaluated as antibody conjugated MMAE or
acMMAE), and unconjugated MMAE were quantified in cynomolgus
monkeys for single (0.3, 1, or 3 mg/kg), and multiple doses (3 or
5 mg/kg, every-three-weeks for 4 doses). The PK data of MMAE in
cynomolgus monkeys, after intravenous administration of MMAE at
single doses (0.03 or 0.063 mg/kg), was included in the analysis. A
semi-mechanistic model was developed and parameter estimates
were obtained by simultaneously fitting the model to all PK data using
a hybrid ITS-MCPEM method.
Results The final model well described the observed Tab,
acMMAE and unconjugated MMAE concentration-time profiles.
Analysis suggested that conjugate is lost via both proteolytic
degradation and deconjugation, while unconjugated MMAE in
systemic circulation appears to be mainly released via proteolytic
degradation of the conjugate.
Conclusions Our model improves the understanding of ADC
catabolism, which may provide useful insights when designing
future ADCs.
KEY WORDS antibody-drug conjugate . integrated modeling .
multiple analytes . pharmacokinetics
ABBREVIATIONS
acMMAE Antibody conjugated monomethyl auristatin E
ADC Antibody-drug conjugate
Amd MMAE formation via ADC antibody
deconjugation pathway
Amp Total MMAE formation via ADC antibody
proteolytic degradation pathway
CLd Distributional clearance of ADC
CLL Chronic lymphocytic leukemia
CLm Systemic clearance of unconjugated MMAE
from the central compartment
CLmd Distributional clearance of unconjugated MMAE
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CV Coefficient of variation
DAR Drug to antibody ratio
ECD Extracellular domain
ELISA Enzyme linked immunosorbent assay
Emax Maximal target-mediated proteolytic degrada-
tion rate of ADC
FcRn Neonatal Fc receptor
Fmd Fraction of formation of unconjugated MMAE
in the central compartment from the
deconjugation pathway of ADC
Fmp Fraction of formation to unconjugated MMAE
in the central compartment from the proteo-
lytic degradation pathway of ADC
HIC Hydrophobic interaction chromatography
ITS-MCPEM Iterative-2-Stage and Monte-Carlo Expecta-
tion-Maximization
KADCn The deconjugate rate constant of the DARn
moiety of the ADC
Km Concentration of ADC to reach half of the
maximal Emax
LC-MS/MS Liquid chromatography-tandem mass
spectrometry





MMAE Monomethyl auristatin E







Vc Central volume of distribution for ADC
Vm Central volume of distribution for unconjugat-
ed MMAE
Vmp Peripheral volume of distribution for unconju-
gated MMAE
Vp Peripheral volume of distribution for ADC
Xmc Amount of unconjugated MMAE in the central
compartment
Xmp Amount of unconjugated MMAE in the pe-
ripheral compartment
Xnc amount of the DARn moiety of ADC in the
central compartment
Xnp Amount of the DARn moiety of ADC in the
peripheral compartment
κ Weibull shape parameter.
λ Weibull scale parameter
INTRODUCTION
Antibody-drug conjugates (ADCs) are a novel class of thera-
peutic agents that enable targeted delivery of cytotoxic che-
motherapeutic agents while reducing their systemic exposure
by linking the cytotoxic drug to a targeted monoclonal anti-
body (mAb). ADCs combine the targeting property and fa-
vorable pharmacokinetics (PK) of a mAb with the cytotoxic
properties of highly potent cytotoxic agents to provide a class
of drugs with an improved therapeutic window. Currently,
two ADCs, ado-trastuzumab emtansine (Kadcyla™) (1) and
brentuximab vedotin (ADCETRIS™) (2) have been approved
by the U.S. Food and Drug Administration, and at least 20
investigational ADCs are in different stages of development
for treating solid tumors and hematological malignancies
(3,4). The linker component, which links the antibody with
the cytotoxic agent, is an essential part of ADC design and
determines the stability of an ADC in vivo (3). Several linker
types, including acid labile linker, protease labile linker, non-
cleavable linker and disulfide linker have been used for these
ADCs (3).
Several monomethyl auristatin E (MMAE) containing ADCs
using the protease-labile di-peptide linker (maleimidocaproyl-
valine-citrulline-p-aminobenzoyloxycarbonyl [MC-VC-PABC])
(Genentech data on file) are in clinical development (Fig. 1). Each
MMAE containing ADC is administered as a mixture of com-
ponents with different drug to antibody ratios (i.e., different DAR
species), ranging from 0 to 8 molecules of cytotoxic drugs per
antibody molecule, with an average DAR of approximately 3.5-
3.6 (Genentech data on file).
ADCs demonstrate a unique mechanism of action and
complex composition and their distribution, catabolism and
elimination processes are not yet well understood. Hypothet-
ically, an ADC may be eliminated via multiple complex
pathways that are related to the antibody component (e.g.,
proteolytic degradation pathway) and the physiochemical
properties of the linkers (e.g., deconjugation pathway) (6,7).
Similar to typical mAbs, ADCs can undergo proteolytic deg-
radation mediated by target-specific or nonspecific cellular
uptake and the neonatal Fc receptor (FcRn)-mediated
recycling process, to break down the ADC and generate the
unconjugated cytotoxic drug. Furthermore, ADCs may un-
dergo chemical and enzymatic processes (e.g., maleimide
exchange) that deconjugate the drug molecules from the an-
tibody component (8), and generate the unconjugated drugs
or other related catabolites. This process converts high DAR
species to low DAR species or unconjugated antibody. With
ADC catabolism, the concentrations of individual DAR spe-
cies change with time, and the average DAR decreases over
time. This was observed for trastuzumab emtansine (T-DM1),
an ADC composed of trastuzumab and the cytotoxic drug
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DM1 via a non-cleavable thioether linker, when administered
to cynomolgus monkeys (9). A hypothetical catabolism scheme
of a MMAE containing ADC is shown in Fig. 2.
Considering the complex catabolism pathways associated
with both the mAb and the drug component post ADC
administration, multiple analytes were measured in systemic
circulation to assess the pharmacokinetic (PK) properties of an
ADC. For the MMAE containing ADCs, these analytes usu-
ally include total antibody (Tab) (sum of conjugated, partially
unconjugated and fully unconjugated antibody), conjugate
(evaluated as antibody-conjugated MMAE, acMMAE) and
unconjugated MMAE. Preclinical studies suggest that the
toxicity profile of an MMAE containing ADC is consistent
with the toxicity profile of MMAE, including reversible bone
marrow toxicity and associated hematopoietic changes
(Genentech data on file). Both the conjugated MMAE and
unconjugated MMAE in the systemic circulation and/or tis-
sue may be associated with antineoplastic efficacy and/or with
toxicity. Therefore, it is important to understand the disposi-
tion pathway of the conjugate and the release mechanism of
unconjugated MMAE into the systemic circulation.
The multiple-analyte integrated PK model was explored
for other ADCs such as T-DM1. A semi-mechanistic integrat-
ed PK model which assumed sequential deconjugation from
high to low DAR species, was developed to describe the PK of
T-DM1 conjugate and total trastuzumab after T-DM1 ad-
ministration in preclinical studies (9–11). This model was then
translated to a semi-mechanistic population PK model with
multiple transit compartments to characterize T-DM1 and
total trastuzumab PK in breast cancer patients (11). A simpli-
fied model was developed that used a one-step deconjugation
process to convert T-DM1 to unconjugated trastuzumab (10),
this successfully described the population pharmacokinetics of
T-DM1 and total trastuzumab in cancer patients. These semi-
Fig. 1 Chemical structure of
MMAE-ADCs with MC-VC-PABC
linker (5). MC: maleimidocaproyl;




Fig. 2 Hypothetical MMAE
containing ADC catabolism
pathways. CL: clearance; mAb:
monoclonal antibody; MMAE:
monomethyl auristatin E; VC:
valine-citrulline
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mechanistic integratedmodels supported the inclusion of both
proteolytic degradation and deconjugation as important
clearance pathways in the hypothetical scheme of T-DM1
catabolism. However, the PK of the unconjugated cytotoxic
drug DM1, an important component of the ADC, was not
integrated into these models, primarily because the DM1
assay quantifies all disulfide bound forms of DM1 instead of
only unconjugated DM1, and most of the observed unconju-
gated DM1 concentrations were below the quantitation limit
of the assay. As a result, none of these models provided insight
into the disposition and major formation route of the uncon-
jugated drug toxin measured in systemic circulation.
CD79b is a signaling component of B-cell receptor restricted
to mature B cells, except for plasma cells (12). It is also expressed
in nearly all types of B cell hematologic malignancies, including
non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leu-
kemia (CLL) (12). Antibodies bound to CD79b are rapidly
internalized, making CD79b ideal for targeted delivery of cyto-
toxic agents conjugated to anti-CD79b mAbs (12–15). An anti-
CD79b-MMAE-containing ADC (12), using a species-specific
antibody that binds to human CD79b, is currently in clinical
development to treat NHL (5). A surrogate form of this ADC
that binds to monkey CD79b receptors was developed for pre-
clinical studies.
The objective of this study was to use the preclinical data of
the surrogate anti-CD79b ADC to develop a semi-mechanistic
integrated model that can simultaneously describe PK of multi-
ple analytes, including Tab, conjugate, and unconjugated
MMAE, forMMAEcontainingADCs based on the hypothetical
catabolism scheme (Fig. 2). This model was then used to inves-
tigate the relationships among the Tab, conjugate, and uncon-
jugated MMAE exposures in order to understand the plausible
pathways of ADC catabolism and unconjugatedMMAE forma-
tion in systemic circulation.
MATERIALS AND METHODS
Antibody Drug Conjugates
The anti-CD79b surrogate ADC, DCDS5017A, has an aver-
age DAR of ~3.5 (i.e., average 3.5 MMAE molecules per
antibody molecule) (Genentech data on file). The initial dis-
tribution of various DAR species in the dosing solution was
quantified by hydrophobic interaction chromatography tech-
nology (HIC). The molecular weight for MMAE is 718 Dal-
tons and the molecular weight for DCDS5017A is 145239
Daltons (Genentech data on file).
Pharmacokinetic Data in Cynomolgus Monkeys
The PK of DCDS5017A was evaluated in cynomolgus mon-
keys after IV administration of a single dose. Three dose levels
(0.3, 1 and 3 mg/kg) were evaluated, and 4 monkeys were
assessed at each dose level. The PK of three analytes, Tab,
acMMAE and unconjugated MMAE were quantified in this
PK study. Blood samples were collected pre-dose, at 5 min,
and at 4, 12, 24, 72, 168, 336, 504, 672, 840 and 1008 h post-
dose. The PK of DCDS5017A was also evaluated in cyno-
molgus monkeys administered repeated 3 or 5 mg/kg doses
every-three-weeks (q3w) for 4 doses. Ten monkeys were
assessed at each dose level. The PK of Tab and unconjugated
MMAE were quantified pre-dose and at 0.25, 6, 24, 72, 168,
336, and 504 h after the first and the fourth (last) q3w doses, as
well as pre-dose and 0.25 h after the second and third q3w
doses.
In addition, the PK of unconjugated MMAE was assessed
in monkeys administered a single IV injection at doses of 0.03
or 0.063 mg/kg MMAE. Ten monkeys were assessed at each
dose level. PK samples were collected pre-dose, at 2, 10, and
30 min post-dose, and at 1, 3, 10, 24, 48, 168, 240 and 504 h
post-dose.
The study protocol was approved by the Testing Facility
Institutional Animal Care andUse Committee (IACUC) prior
to dose administration.
Bioanalytical Methods
Figure 3 shows the components of the three key PK analytes
measured: Tab, conjugate (evaluated as acMMAE) and un-
conjugated MMAE. The bioanalytical methods for Tab and
acMMAE quantify the total concentrations from a heteroge-
neous mixture of various DAR species (16). Tab concentra-
tions (i.e., the sum of concentrations of all DAR species in-
cluding fully conjugated, partially deconjugated and fully
deconjugated antibody) were measured in serum samples
using a validated enzyme linked immunosorbent assay
(ELISA) method. The acMMAE concentrations were mea-
sured in plasma samples using a method consisting of protein
A-affinity capture of the conjugate from plasma followed by
enzyme-mediated release of MMAE and quantitative liquid
chromatography-tandem mass spectrometry (LC-MS/MS).
UnconjugatedMMAEwas measured in plasma samples using
a validated LC-MS/MS method. In cynomolgus monkey
studies, the assay lower limits of quantitation (LLOQ) were
0.05 nM (0.0359 ng/mL) for unconjugated MMAE, and
0.195 nM (0.140 ng/mL) for acMMAE, and the minimum
quantifiable concentration (MQC) for Tab was 0.06 μg/mL.
Model Development and Data Analysis
A semi-mechanistic multi-compartment integrated model was
developed for simultaneous fitting of Tab, acMMAE and
unconjugated MMAE PK data. In this model, the initial dose
input for eachDAR compartment for the conjugate was based
on the initial distribution of various DAR species in the dosing
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solution, as measured by HIC. The following percentages
were obtained for each DAR species: DAR=0, 5.235%;
DAR=1, 0.61%; DAR=2, 30.51%; DAR=4, 48.35%;
DAR=6, 12.755%; DAR=8, 2.545% (Genentech data on
file). The conjugate distribution was described by a two-
compartmental model; the conjugate elimination was as-
sumed to be via both the proteolytic degradation and
deconjugation pathways. Conjugate was assumed to
deconjugate only oneMMAE at a time to sequentially convert
from DARn moiety to DARn-1 moiety, where n=1, 2, 3, 4, 5,
6, 7, 8. During model development, various models were
tested, including proteolytic degradation clearance by either
linear and/or Michaelis-Menten (MM) kinetics, changes in
proteolytic degradation clearance with DAR, deconjugation
in either the central and/or the peripheral compartments, and
various relationships of changes in deconjugation rate con-
stant with DAR. Unconjugated MMAE disposition is de-
scribed by a two-compartmental linear PK model. Both
proteolytic degradation and deconjugation of the ADC
provide input of unconjugated MMAE into the central
compartment of the MMAE disposition model. The Par-
allel Iterative-2-Stage and Monte-Carlo Expectation-Maxi-
mization (ITS-MCPEM) algorithm implemented in the S-
ADAPT II (version 1.57) program, an augmented version
of ADAPT II with population analysis capabilities, was
used to obtain estimates of the final model parameter
value (17,18). Inter-subject variability was assumed to have
a log-normal distribution. Intra-subject variability was
modeled using a proportional error model. Multiple
models that fit the formation of unconjugated MMAE in
systemic circulation were explored and the best model was
chosen based on a log likelihood ratio test for the nested
model (Δ Objective Function Value=10.3 for df=1,
p<0.001) or Schwarz criterion (19) for the non-nested
model. The stringent selection criterion of log likelihood
ratio test was used because of the inherent random noise
associated with the Monte-Carlo sampling technique
employed in the MCPEM algorithm (20). S-PLUS
(Version 8.1, Seattle, WA) was used to generate graphical
output for model fitting and simulations.
RESULTS
A total of 447 Tab, 132 acMMAE, and 454 unconjugated
MMAE concentration data from 52 monkeys were used for
modeling including 32 monkeys receiving DCDS5017A in-
jections and 20 monkeys receiving unconjugated MMAE
injections. A mechanism-based multiple-compartment PK
model (Fig. 4) was developed that adequately described the
PK of Tab, acMMAE and unconjugated MMAE simulta-
neously. Both proteolytic degradation and deconjugation
pathways occur only in the central compartment of the con-
jugate, as the alternative model with these pathways occurring
in the peripheral compartment did not improve the model
fitting. The distribution and proteolytic degradation clear-
ances for each DAR moiety were the same, as the alternative
model with DAR dependent proteolytic clearance did not
improve the model fitting. The proteolytic degradation clear-
ance for the conjugate was described by MM kinetics, as the
alternative model with both linear and MM clearance did not
improve the model fitting.
The representative equations describing the final semi-




















Fig. 3 Analytes measured for MMAE containing ADCs. DAR: drug to antibody ratio; MMAE: monomethyl auristatin E















































Xmc− CLmdVmp Xmp ð8Þ
Where
Amp ¼ 8  Emax X7cKm  VcþX8c þ 7 
Emax X7c
Km  VcþX8c þ…
þ Emax
X0c
Km  Vc þX0c ð9Þ
Amd ¼ 8 KADC8 X8c þ 7 KADC7 X7c þ…
þKADC1 X1c ð10Þ
Fig. 4 Final model structure of semi-mechanistic multiple-analyte population model for MMAE containing ADCs. ADC: antibody-drug conjugate; CLd:
distributional clearance of ADC; CLm: systemic clearance of unconjugated MMAE from the central compartment; CLmd: distributional clearance of unconjugated
MMAE; DAR8c, DAR7c, … DAR1c, DAR0c: concentrations of anti-CD79b-MMAE ADC in the central compartment with DAR=0–8; DAR8p, DAR7p, …
DAR1p, DAR0p: concentrations of anti-CD79b ADC in the peripheral compartment with DAR=0–8; Emax: maximal target-mediated proteolytic degradation
rate of ADC; Fmd: fraction of formation of unconjugated MMAE in the central compartment from the deconjugation pathway of ADC; Fmp: fraction of formation
to unconjugated MMAE in the central compartment from the proteolytic degradation pathway of ADC; KADC8, KADC7, …KADC1: deconjugation rate
constants for each DAR species (DAR=8, 7, …, 1) of the ADC; Km: concentration of ADC to reach half of the maximal Emax; MMAEc: concentration of
unconjugated MMAE in the central compartment; MMAEp: concentration of unconjugated MMAE in the peripheral compartment; Vc: central volume of
distribution for ADC; Vp: peripheral volume of distribution for ADC; Vm: central volume of distribution for unconjugated MMAE; Vmp: peripheral volume of
distribution for unconjugated MMAE
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Xnc (e.g., X8c, X7c, etc.,) and Xnp (e.g., X8p, X7p, etc.,)
represent the amount of the DARn moiety of ADC in the
central and peripheral compartments, respectively. The Xmc
and Xmp represent the amount of unconjugated MMAE in
the central and peripheral compartments, respectively. Vc
and Vp represent central and peripheral volumes of distribu-
tion for the ADC. CLd represents the inter-compartmental
clearance. Emax and Km are the Michaelis-Menten kinetic
constants for the nonlinear proteolytic degradation of ADC
antibody from the central compartment. CLm is the systemic
clearance of unconjugated MMAE from the central compart-
ment, and CLmd is the inter-compartmental clearance of
unconjugated MMAE. Vm and Vmp are the central and
peripheral volumes of distribution for unconjugated MMAE,
respectively. Fmd represents the fraction of unconjugated
MMAE released from the deconjugation pathway of the
ADC in the central compartment, and Fmp is the fraction of
unconjugated MMAE released from the proteolytic degrada-
tion pathway of the ADC in the central compartment. Amp
and Amd are the total MMAE formation via ADC antibody
proteolytic degradation and deconjugation pathways, respec-
tively. KADCn (e.g., KADC8, KADC7, etc.) represents the
deconjugate rate constant of the DARn moiety of the ADC.
The relationship between deconjugation rate and DAR is best
described by the Weibull distribution function presented be-
low:
KADCn ¼ K  κλ 
x
λ
  κ−1ð Þ
 e− xλð Þ
κ
ð11Þ
κ and λ are theWeibull constant and x=8-n, where n is the
DAR; K is fixed to 1 h−1. In this case, the highest conjugation
rate was observed with the moiety with the largest number of
DAR.
The parameters of the final model are summarized in
Table I. All these parameters were estimated with good preci-
sion (% coefficient of variation (CV) <50). The Vc for the
conjugate (0.0990 L or ~39.6 mL/kg, assuming 2.5 kg as
typical body weight of a cynomolgus monkey) was approxi-
mately equal to the plasma volume, as expected for a mAb
(21,22). The Emax andKm for the nonlinear pharmacokinetics
of DCDS5017A were 0.0407 h−1 and 0.959 nmol/L, respec-
tively. The λ (scale parameter) and κ (shape parameter) of the
Weibull distribution function for the deconjugation rate con-
stant of DCDS5017A were 1.51 and 1.10, respectively. Fmp,
the fraction of formation of unconjugated MMAE from the
proteolytic degradation pathway of DCDS5017A, was estimat-
ed to be 0.783, suggesting that 78.3% of MMAE released from
proteolytic degradation contributes to the systemic level of
unconjugated MMAE. Fmd, the fraction of formation of un-
conjugated MMAE from the deconjugation pathway of
DCDS5017A was estimated to be 0.0242, suggesting that only
2.42% of the MMAE containing catabolites formed from the
deconjugation pathway contributed to the systemic level of
unconjugated MMAE. Therefore, the majority of systemic
unconjugated MMAE may be released from proteolytic deg-
radation rather than deconjugation of the ADC.
For unconjugated MMAE, the elimination and distribution
clearance (CLm and CLmd) values were 2.27 L/h and 23 L/h,
respectively. The central distribution volume (Vm) was 1.00 L,
10-fold larger than the central distribution volume of
DCDS5017A. Unconjugated MMAE distributed widely into
tissues with a peripheral tissue volume (Vmp) of 88.4 L. The
typical distribution and elimination half-lives of the unconjugated
MMAE were estimated to be 0.0272 h and 29.9 h, respectively.
The final model reasonably predicted the observed Tab,
acMMAE, and unconjugated MMAE PK profiles after ad-
ministration of either DCDS5017A or unconjugatedMMAE.
Figure 5 presents individual predicted versus observed data for
all three analytes in all animals. Generally, there was good
agreement between the predicted and observed data, and the
diagnostic plots (Fig. 5) of the final model identified no sys-
tematic bias. Representative plots of observed and model
predicted Tab, acMMAE and unconjugated MMAE concen-
trations in 3 animals received 0.3, 1, or 3 mg/kg doses of
DCDS5017A as shown in Fig. 6. In addition, the model
adequately described the observed unconjugated MMAE-
time profiles after IV administration of different doses of
MMAE (Fig. 7). These plots together with the visual predictive
check plots (Supplementary Figure 1) further demonstrate
that the final model reasonably described the data.
The Weibull model described best the relationship be-
tween deconjugation rate constant and DAR. The
deconjugation rate constant decreased from 3.52 to less than
0.01 h−1 for DAR8 and DAR1 species, respectively (Fig. 8), as
computed by model parameters. Using the individual param-
eters obtained from the final model, the amount of unconju-
gated MMAE formed by both pathways were simulated and
calculated. Figure 9a-c show the unconjugated MMAE
release-time profiles via deconjugation or the proteolytic deg-
radation pathway from the corresponding animals presented
in Fig. 6 that received a single-dose of conjugate in 0.3, 1, and
3 mg/kg. The results suggested that plasma exposure to
unconjugated MMAE appears to be affected mainly by the
proteolytic degradation pathway rather than the
deconjugation pathway. Figure 9d summarizes the percentage
of unconjugated MMAE release via conjugate proteolytic
degradation in the studied population to be 98% after a single
dose of ADC (mean: 94%; range: 61–99%).
DISCUSSION
After administration to cynomolgus monkeys, MMAE-
containing ADCs exhibited complex PK involving multiple
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analytes including Tab, conjugate (evaluated as acMMAE)
and unconjugatedMMAE. Themodel developed in this study
was established based on the hypothetical ADC catabolism
schemes (Fig. 2). The model well described the observed PK
Table I Model Parameters for the Final Integrated Model
Parameters Population mean (%CV) Inter-individual variability (%CV)
ADC
Emax (1/h) 0.0407 (5.5) 0.0945 (25.4)
Km (nmol/L) 0.959 (1.68) ––
Vc (L) 0.0996 (2.6) 0.0118 (36.9)
CLd (L/h) 0.00197 (1.9) –
Vp (L) 0.183 (8.7) 0.230 (25.4)
λ [Weibull scale parameter] 1.51 (0.9) –
κ [Weibull shape parameter] 1.10 (0.6) –
Fmp 0.783 (2.2) –
Fmd 0.0242 (30.9) 1.78 (34.2)
MMAE
CLm (L/h) 2.27 (8.3) 0.333 (20.2)
Vm (L) 1.00 (0.3) –
CLmd (L/h) 23.0 (0.7) –
Vmp (L) 88.4 (4.8) 0.0670 (31.9)
σacMMAE [Residual error for acMMAE] 0.257 (4.6) –
σAb [Residual error for Tab] 0.194 (4.1) –
σMMAE [Residual error for unconjugated MMAE] 0.327 (8.9) –
ADC: antibody-drug conjugate; CLd: distributional clearance of ADC; CLm: systemic clearance of unconjugated MMAE from the central compartment; CLmd:
distributional clearance of unconjugated MMAE; CV: coefficient of variation; Emax: maximal target-mediated proteolytic degradation rate of ADC; Fmd: fraction of
formation of unconjugated MMAE in the central compartment from the deconjugation pathway of ADC; Fmp: fraction of formation to unconjugated MMAE in the
central compartment from the proteolytic degradation pathway of ADC; Km: concentration of ADC to reach half of the maximal Emax; MMAE: monomethyl
auristatin E; Vc: central volume of distribution for ADC; Vp: peripheral volume of distribution for ADC; Vm: central volume of distribution for unconjugated
MMAE; Vmp: peripheral volume of distribution for unconjugated MMAE
Fig. 5 Standard model diagnostic
plots for all three analytes. CWRES:
conditional weighted residual; DV:




population predictions; Time: PK
time after the first dose.
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Fig. 6 Individual fitting plots for a representative subject after a single dose of (a) 0.3 mg/kg, (b) 1 mg/kg, and c) 3 mg/kg of anti-CD79b ADC. Dashed line:
concentration level of≤LLOQ or≤MQC; open circle: observed PK concentrations; open circles on the dashed line: observed PK concentrations with≤LLOQ or
≤MQC values; solid line: individual model prediction; Tab: total antibody; acMMAE: antibody-conjugated MMAE; MMAE: monomethyl auristatin E.
Fig. 7 Individual fitting plots for a representative subject after a single dose of (a) 0.03mg/kg, and (b) 0.063mg/kg of IVMMAE.Dashed line: concentration level of
below quantification limit (BQL); open circle: observed PK concentrations; solid line: individual model prediction; MMAE: monomethylauristatin E.
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data of MMAE-containing ADC and suggested that the con-
jugate was eliminated by both deconjugation and proteolytic
degradation pathways while the unconjugated MMAE in the
systemic circulation was mainly formed by proteolytic degra-
dation of the conjugate.
The model allows a simultaneous estimation of both the
deconjugation and proteolytic degradation clearance for the
conjugate, because the PK data in cynomolgus monkeys for
both Tab and conjugate (acMMAE) are used. Hypothetically,
conjugate (acMMAE) is cleared by both deconjugation and
proteolytic degradation while total antibody is only cleared by
proteolytic degradation. This additional clearance pathway of
deconjugation for acMMAE is supported by the observed
faster clearance of acMMAE compared to Tab.
To derive the final model in this study, many alternative
models were tested during model development. It was report-
ed that the highDAR species are less stable in vitro, more prone
to aggregation and fragment formation (23) and cleared faster
in vivo than low DAR species (24,25). Using affinity capture
LC-MS, it was found that after T-DM1 administration to
cynomolgus monkeys, high DAR species cleared much faster
Fig. 8 Simulated deconjugation rate based on Weibull model. ADC: anti-
body-drug conjugate; MMAE: monomethyl auristatin E.
Fig. 9 Unconjugated MMAE release-time profile for a representative subject after a single dose of a) 0.3 mg/kg, b) 1 mg/kg, and c) 3 mg/kg of anti-CD79b-
MMAE ADC. d) Mean percentage of unconjugated MMAE release due to conjugate proteolytic degradation after a single dose of ADC. Solid line – unconjugated
MMAE release via Antibody (Ab) proteolytic degradation; dashed line – unconjugated MMAE release via deconjugation pathway; dotted line – percent of
unconjugated MMAE release via conjugate proteolytic degradation pathway.
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than low DAR species. There was also an increase of DAR1
and DAR0 species after dosing, suggesting the conversion of
high DAR species to low DAR species potentially due to
deconjugation (25). However, it is not clear whether the data
suggest a faster proteolytic degradation, or deconjugation, or
both processes, for the high DAR species. By comparing the
PK of cAC10-vc-MMAE with DAR of 8, 4, or 2, or uncon-
jugated antibody in SCID mice, using the ELISA assay to
quantify the Tab, the clearance of DAR=8 ADCs was found
to be 3–4 fold higher than the DAR=2 or 4 ADCs and
unconjugated antibody, suggesting a potentially faster proteo-
lytic degradation for DAR=8 ADCs in mice (24). Based on
these findings, simpler models using DAR dependent change
of proteolytic degradation or deconjugation were constructed
first and served as the basis for developing more complex
models. In this model, the conjugate distribution was de-
scribed by a two-compartmental model and eliminated via
nonlinear proteolytic degradation clearance, and
deconjugated via DAR-dependent simple linear process, and
unconjugated MMAE disposition was described by a two-
compartmental linear PK model. For the proteolytic degra-
dation clearance, it is possible that instability of the high DAR
species may be due to the high proteolytic clearance. Howev-
er, including the DAR-dependent proteolytic degradation
process and additional PK data from the naked CD79b
antibody failed to improve the model fit. It is worth noting
that in the current study, a mixture of various DAR species
were injected into monkeys, and only 15% of the total dose
comprised of DAR=8 or 6 species while the majority were
DAR 4 or 2 species (>80% of total dose). It was reported that
DAR=4 or 2 species have relatively similar proteolytic deg-
radation clearance (24) and in vitro thermal stability (23),
compared to DAR=8 or 6 species. Given this, and without
PK characterization of individual DAR species, the model
may not have sufficient data to estimate DAR dependent
proteolytic degradation clearance. Therefore, a DAR-
independent elimination process similar to several previously
published mechanism-based ADC models, was used to de-
scribe the proteolytic degradation clearance process of all
DAR species in the MMAE-containing ADC (9,11).
For the deconjugation clearance, replacing the constant
rate model with the more flexible Weibull model to describe
the relationship between deconjugation rate constant and
DAR significantly improved the model fit based on Schwarz
criterion (Fig. 8). This suggests that conjugate species with
high DARs deconjugate much faster than species with low
DARs. The MMAE containing ADC with maleimide linkers
is manufactured by conjugation through reduced interchain
disulfide bonds. This process results in a heterogeneous mix-
ture of ADCmolecules with a range of different DARs from 0
to 8 (16). Solvent accessibility and local charge can impact the
in vivo stability of the conjugate owing to deconjugation by
maleimide exchange with reactive thiols in albumin, free
cysteine, or glutathione (8). The faster deconjugation rate of
high DAR species may be due to a higher probability of
unloading toxin molecules when there are relatively high
numbers of toxin molecules per molecule of antibody with
greater inherent instability impacted by the chemical and
structural dynamics of the conjugation site.
Based on the ADC mechanism of action, the proteolytic
degradation and deconjugation of the conjugate may occur at
tissue sites after cellular uptake to form unconjugated MMAE
in the tissue, which back diffuse to the systemic circulation.
However, alternative models that incorporated proteolytic or
deconjugation clearances of the conjugate in the peripheral
compartments (i.e., tissue sites) did not improve the fitting,
possibly due to that only serum/plasma concentrations of
each analyte were collected in the study. Additional work to
understand the proteolytic degradation and deconjugation of
ADCs in the tissue would be helpful to assess alternative
models.
Similar to mAbs, proteolytic degradation of an ADC is
mediated by target-mediated clearance and FcRn mediated
recycling after non-specific cellular uptake. For the MMAE
containing ADCwithMC-VC-PABC linkers, proteolytic deg-
radation may also be impacted by the inherent instability of
the conjugate due to the potential disruption of interchain
disulfide bonds. In the current model, both linear and nonlin-
ear clearance were tested to describe the proteolytic degrada-
tion of the conjugate; however, only a single nonlinear clear-
ance appeared sufficient to describe the data and was used in
the final model.
During the development of the final model, the visual
predictive check revealed that the presence of several Tab,
acMMAE, and MMAE concentrations below LLOQ ham-
pered the ability to characterize the time-course of these
analytes using the standard modeling and data handling ap-
proach (Fig. 6). Therefore, a likelihood based approach was
used to develop the final model, which included all observa-
tions with LLOQ values as censored data in the analysis (26).
This method has been successfully used to develop several
mechanism-based models for describing the anti-therapeutic
antibody- and/or receptor-mediated nonlinear PK of a ther-
apeutic monoclonal IgG antibody using PK data with many
observations below LLOQ, and allowed us to obtain reliable
model parameter estimates by fitting the developed model
simultaneously to all data with many MQC observations
(20,27).
Both deconjugation and proteolytic degradation of the
conjugate were assumed to contribute to the formation of
unconjugated MMAE in the systemic circulation, and the
fraction of formation from either deconjugation or proteolytic
degradation was estimated. With the model parameters of
unconjugated MMAE uniquely identified by the PK data in
cynomolgus monkeys after IV unconjugated MMAE admin-
istration, the input function or formation of systemic
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unconjugated MMAE after conjugate dosing can be deter-
mined. The values for the fraction parameters suggest the
proteolytic degradation of the conjugate provides the major
source of unconjugated MMAE in the systemic circulation.
This could be explained by the fact that deconjugation mainly
forms MMAE containing catabolites (e.g., cys-vc-MMAE)
which are not measured by the LC-MS/MS method that
was developed for quantifying MMAE only. This finding is
consistent with results reported by Shah et al., using another
mechanism-based PK model to predict conjugate and uncon-
jugated drug concentrations in plasma and tumor tissue (28).
It was found that clearance of the entire ADC (similar to the
proteolytic degradation pathway described herein) seemed to
be a higher contributor of released payload (cytotoxic drugs)
in plasma than the payload dissociated from intact ADC
(similar to the deconjugation pathway described herein).
Our current analysis suggests that a decrease of proteolytic
degradation clearance may potentially decrease the systemic
level of unconjugated MMAE. Proteolytic degradation is
composed of target-mediated clearance and FcRn recycling
pathway-mediated non-specific cellular uptake and degrada-
tion. Target-mediated proteolytic degradation is desirable for
efficacy, while non-specific uptake and degradation may be
related to toxicity. This analysis suggests that enhancing
FcRn-mediated recycling by antibody engineering techniques
may be beneficial in reducing non-specific degradation of the
conjugate and generation of unconjugated MMAE in system-
ic circulation, hence decreasing the undesirable toxicity.
One potential limitation of our final model was that the
unconjugated MMAE concentrations after ADC dosing were
relatively low compared to those observed after single IV
MMAE study. Therefore, the potential nonlinearity of the
MMAE PK profiles at low concentrations may affect the
results in this study. To our knowledge, the PK of the low
dose MMAE in cynomolgus monkeys and other species was
never reported in the literature besides this paper. However, a
recent published PBPK model which assumed linear MMAE
PK well described the observed unconjugated MMAE-time
profiles after ADC administrations (29). Therefore, we believe
that linear MMAE PK assumption used in this study was
reasonable in the absence of PK data for low dose MMAE,
but more study with low dose MMAE PK data is desirable in
order to confirm this study result.
The currentmodel may be further extended to clinical data
to understand the quantitative relationship of Tab, acMMAE
and unconjugated MMAE in patients. Furthermore, the
pharmacokinetic-pharmacodynamic model will also be useful
for correlating PK with efficacy and safety endpoints to inves-
tigate the systemic exposure of which analyte(s) is best corre-
lated with clinical responses. For brentuximab vedotin, the
concentrations of the conjugate in the systemic circulation
correlated with the probability of tumor response, neutrope-
nia, and peripheral neuropathy, while the concentrations of
unconjugated MMAE did not correlate with efficacy and
safety outcomes (30). Additional development of the model
to project the tissue concentrations of the conjugate and
unconjugated MMAE would be highly valuable to correlate
with efficacy and safety profiles in patients.
As the unconjugated antibody species may form after ADC
dosing, which may hypothetically exhibit competitive binding
to the targets with the drug containing conjugate, it is of
interest to estimate the DAR=0 species PK after ADC dosing.
The model applies to simulating the PK profiles of each DAR
moiety, specifically the DAR=0 species PK for various dosing
regimens of the conjugate, to assess whether there is accumu-
lation of this species after repeated dosing with different dosing
regimens. The final model well described the observed data.
However, precise quantification of ADC distribution, catab-
olism and elimination is still in its infancy and future experi-
ments are needed to confirm the findings of this model anal-
ysis. While the final model in this study can describe the
complex PK ofMMAE-containing ADCs, it is also considered
a plausible model based on the current hypothesis and avail-
able assay/data for multiple analytes. This model represented
an important first step to understand the complex catabolism
and unconjugated drug formation for MMAE-containing
ADCs and could serve as the base model to build future
generations of PK and systems pharmacology models based
on our increasing understanding of ADC catabolism.
CONCLUSIONS
Two mechanisms were proposed to describe ADC conjugate
catabolism: deconjugation and proteolytic degradation. The
integrated semi-mechanistic model reported here adequately
described the observed concentration-time profiles of Tab,
acMMAE and unconjugated MMAE in cynomolgous mon-
keys administered anti-CD79b-MMAE containing ADC.
Modeling results suggested that conjugated MMAE in ADC
is eliminated via both deconjugation and proteolytic degrada-
tion; whereas unconjugated MMAE in systemic circulation
appears to be released mainly via the proteolytic degradation
pathway. This analysis supports the current understanding of
ADC catabolism and sheds light on the potential release
mechanisms of unconjugated MMAE into the systemic circu-
lation, which may provide valuable insights for future ADC
design.
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